A multicenter Phase III trial found that intravenous tirofiban did not outperform standard oral antiplatelet therapy for 90-day functional outcomes in acute branch atheromatous disease-related stroke. The result narrows options for a clinically defined stroke subtype and reinforces the challenge of translating acute pharmacologic intensification into durable disability improvements. The trial adds to a growing body of evidence that stronger or alternative antiplatelet approaches may not necessarily improve functional recovery even when mechanistic rationale is strong. The endpoint selection—functional outcomes at 90 days—was the decisive measure of comparative benefit. For the pipeline, the study is a signal to re-check trial design assumptions in this niche population, including patient stratification and treatment windows, especially where current standards already set a high bar for incremental effect.